anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a single-arm phase II trial assessing the antitumor activity as measured by progression free survival of perifosine in patients with metastatic RCC who have progressed on sorafenib or sunitinib. A total of 48 patients will be enrolled in the trial. All subjects will have histologically confirmed metastatic RCC with predominantly clear cell features (≤ 50% other histologic features). Patients who have been taken off sorafenib or sunitinib may only have been off therapy for less than three months prior to study enrollment. Patients who remain on sorafenib or sunitinib may continue on drug at their current dose until two weeks prior to the initiation of perifosine therapy.

The study consists of three periods: pre-treatment/screening, treatment, and follow-up. Day 1 will be defined as the first day of perifosine therapy. Patients will remain in the treatment phase until progression or toxicity. Patients will be seen by an MD every 3 weeks with 6 weeks defining one cycle of therapy. Tumor evaluations will occur every 6 weeks.
We present the case of a 76-year-old male with mild cognitive impairment and delirium who was referred to consultation-liaison psychiatry for an assessment of capacity to choose discharge. Cases involving "dispositional capacity" are complex and increasingly frequent, with momentous consequences for patients and their families, but are rarely discussed in the literature. In this article, experts in functional assessment, cognition, and ethics provide guidance for this commonly encountered clinical scenario based on their experience and available literature. We review the content and formulation of occupational and physical therapy assessments and their utility to the consultation-liaison psychiatrist. We also examine the relationship of cognitive impairment to decisional capacity and offer suggestions on a structured approach to evaluation. Finally, we discuss the ethical and systemic considerations of dispositional capacity and explore potential pitfalls that can lead to interprofessional conflict and missed opportunities in patient care.
CIVO is a research tool composed of a hand-held single-use sterile injector coupled with fluorescent tracking microspheres called CIVO GLO that mark the sites of drug microdose injection, enabling rapid assessment of multiple oncology drugs or drug combinations simultaneously within a patient's tumor. In this Phase 0 intratumoral microdosing study in human patients with pathologic diagnosis of HNSCC with at least one lesion (primary, recurrent, or effaced metastatic lymph nodes) for which there is a planned surgical intervention, we will evaluate motolimod's ability to activate immune effector cells within the local tumor microenvironment. Additionally, this study will examine motolimod in combination with nivolumab to study whether motolimod enhances the localized immune responses compared to those of either immunotherapy alone. Motolimod singly and in combination with nivolumab will be delivered intratumorally in subtherapeutic microdose quantities via CIVO.

The CIVO device penetrates solid tumors and delivers subtherapeutic microdoses of up to eight anti-cancer agents or combinations of anti-cancer agents co-injected with CIVO GLO into discrete regions of the tumor. At the time of the planned surgical intervention (at least four hours to up to four days after the CIVO microdose injection), the injected tumor tissue is then excised and tumor responses are assessed via histological staining of tumor cross-sections sampled perpendicular to each injection column. Co-injection with CIVO GLO enables identification of each injection site during resection as well as in tissues stained for analysis. Because the platform delivers microdose amounts of each test agent or combination directly into the patient's tumor tissue, hypotheses can be tested earlier in the drug development process, consistent with the goals of the 2006 FDA Exploratory IND Guidance for Industry.
The invention discloses amide compounds shown in a formula (I) or pharmaceutically acceptable salts and a preparation method thereof. According to the preparation method I, a compound II and a compound III generate a coupling reaction under an inert gas in an anhydrous solvent under the effect of a condensation reagent. In addition, the invention further discloses an application of the compounds shown in the formula (I) in preparation of a reagent for inhibiting thrombin or a medicine for treating and/or preventing thrombin-mediated and/or thrombin-associated diseases. The invention further provides an application of the compounds shown in the formula (I) in preparation of an active medicine for regulating or inhibiting serine protease of tryptase. The invention further discloses medicine compositions which comprise the compounds shown in the formula (I) and pharmaceutically acceptable carriers of the compounds. The amide compounds disclosed by the invention have excellent thrombin inhibiting activity and are suitable for preparing various medicine preparations.
BACKGROUND: Axillary disease extent according to baseline [18F]fluorodeoxyglucose PET/CT combined with pathological axillary treatment response has been proposed to guide de-escalation of axillary treatment for clinically node-positive breast cancer patients treated with neoadjuvant systemic therapy. The aim of this study was to assess whether axillary disease extent according to baseline [18F]fluorodeoxyglucose PET/CT and breast cancer molecular subtype are predictors of axillary pCR.
METHODS: This study included clinically node-positive patients treated with neoadjuvant systemic therapy in the prospective Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy ('RISAS') trial (NCT02800317) with baseline [18F]fluorodeoxyglucose PET/CT imaging available. The predictive value of axillary disease extent according to baseline [18F]fluorodeoxyglucose PET/CT and breast cancer molecular subtype to estimate axillary pCR was evaluated using logistic regression analysis. Discriminative ability is expressed using ORs with 95% confidence intervals.
RESULTS: Overall, 185 patients were included, with an axillary pCR rate of 29.7%. The axillary pCR rate for patients with limited versus advanced baseline axillary disease according to [18F]fluorodeoxyglucose PET/CT was 31.9% versus 26.1% respectively. Axillary disease extent was not a significant predictor of axillary pCR (OR 0.75 (95% c.i. 0.38 to 1.46) (P = 0.404)). There were significant differences in axillary pCR rates between breast cancer molecular subtypes. The lowest probability (7%) was found for hormone receptor+/human epidermal growth factor receptor 2- tumours. Using this category as a reference group, significantly increased ORs of 14.82 for hormone receptor+/human epidermal growth factor receptor 2+ tumours, 40 for hormone receptor-/human epidermal growth factor receptor 2+ tumours, and 6.91 for triple-negative tumours were found (P < 0.001).
CONCLUSION: Molecular subtype is a significant predictor of axillary pCR after neoadjuvant systemic therapy, whereas axillary disease extent according to baseline [18F]fluorodeoxyglucose PET/CT is not.
The use of tools such as foam rollers or massage balls to resolve myofascial tension is highly preferred by both therapists and patients. It is theorized that the sweeping pressure generated during rolling causes the fascia to stretch and increase the range of motion. In addition, the warming caused by the friction during rolling can dissolve the adhesions between the fascial layers and restore the elasticity of the myofascial tissues. In addition to similar mechanical effects, the use of cork balls with magnetic properties is becoming increasingly common. Studies have shown that static magnetic magnets reduce pain, increase microcirculation and oxygenation and cause changes in presynaptic membrane function. As far as we know, there is no study examining the myofascial relaxation effect of magnetic balls in the literature. Evaluating the clinical impact and efficacy of this device which allow the person to perform self-massage might contribute the current literature. This study was planned to evaluate the myofascial relaxation caused by two different fascial cork balls with and without magnetic properties.
TMS treatment indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
UNLABELLED: Adipose tissue within the tumor microenvironment (TME) plays a critical role in supporting breast cancer progression. In this study, we identified FAM3 metabolism-regulating signaling molecule C (FAM3C) produced by cancer-associated adipocytes (CAA) as a key regulator of tumor progression. FAM3C overexpression in cultured adipocytes significantly reduced cell death in both adipocytes and cocultured breast cancer cells while suppressing markers of fibrosis. Conversely, FAM3C depletion in CAAs resulted in adipocyte-mesenchymal transition (AMT) and increased fibrosis within the TME. Adipocyte FAM3C expression was driven by TGFβ signaling from breast cancer cells and was reduced upon treatment with a TGFβ-neutralizing antibody. FAM3C knockdown in CAAs early in tumorigenesis in a genetically engineered mouse model of breast cancer significantly inhibited primary and metastatic tumor growth. Circulating FAM3C levels were elevated in patients with metastatic breast cancer compared with those with nonmetastatic breast cancer. These results suggest that therapeutic inhibition of FAM3C expression levels in CAAs during early tumor development could be a promising approach in the treatment of patients with breast cancer.
SIGNIFICANCE: High FAM3C levels in cancer-associated adipocytes contribute to tumor-supportive niches and are tightly associated with metastatic growth, indicating that FAM3C inhibition could be beneficial for treating patients with breast cancer.
PURPOSE:To obtain a new derivative, having strong 5-HT3 antagonistic action and useful as an antiemetic agent. CONSTITUTION:A derivative of formula I (R1 is lower alkyl, lower alkoxy, etc.; R2 is H, methyl, etc. ; R3 is halogen or methyl; R4 is H or amino) or its pharmacologically permissible acid addition salt, e.g. 5-chloro-1-ethyl-2-(4- methyl-1-piperazinyl)benzimidazole. This compound of formula I is obtained by reacting a compound of formula II with phosphorus oxychloride in an amount of 2-6 equiv. based on the compound of formula II in or without an inert solvent, e.g. chloroform at 60 deg.C) to the boiling point temperature of the solvent for 0.5 to 4hr, providing a compound of formula III and then reacting the resultant compound of formula III with a compound of formula IV in an amount of 2-6 equiv. based on the compound of formula III in or without an inert solvent such as xylene at 80-160 deg.C or the boiling point temperature of the solvent for 1-4hr.
SUNOSI contains solriamfetol, a dopamine and norepinephrine reuptake inhibitor (DNRI). Solriamfetol is a phenylalanine derivative with the systematic name (R)-2-amino-3-phenylpropylcarbamate hydrochloride.

The molecular formula is C10H15N2O2Cl, and the molecular weight is 230.69.

The chemical structure is:

Solriamfetol hydrochloride is a white to off-white solid that is freely soluble in water.

SUNOSI tablets are intended for oral administration. Each 75 mg SUNOSI film-coated tablet contains 75 mg solriamfetol (equivalent to 89.3 mg solriamfetol hydrochloride). Each 150 mg SUNOSI film-coated tablet contains 150 mg solriamfetol (equivalent to 178.5 mg solriamfetol hydrochloride). The inactive ingredients are hydroxypropyl cellulose and magnesium stearate. In addition, the film coating contains: iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
Rheumatic heart disease (RHD) remains the leading cardiac problem affecting pregnant women, especially in low- to middle-income countries. In nearly one-third of the cases, it is detected during pregnancy when they present with complications. Infective endocarditis (IE) in pregnancy is rare, with an incidence of 1 in 100 000 pregnancies, and carries high maternal and fetal morbidity and mortality. Embolisation of the infective vegetation can lead to inoculation of the arterial wall, causing aneurysm, infarction or abscess formation. Being an end artery, splenic artery aneurysm and infarct can complicate IE; it can even be lethal due to ruptured aneurysm with intraperitoneal bleed. We report a patient who presented with IE complicated with a splenic-artery aneurysm during pregnancy, successfully managed by a multidisciplinary team.
This an open-label study in which all participants will have their valbenazine dose titrated from 40 mg to 80 mg per day, which will remain the valbenazine dose through end of study, unless interrupted by adverse events. Participants taking valbenazine who are concurrently taking strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, duloxetine) will continue their valbenazine dose at 40 mg per day through end of study. Participants taking valbenazine who are concurrently taking strong CYP3A4 inhibitors (ketoconazole, fluconazole, cimetidine, verapamil) will continue their valbenazine dose at 40 mg per day through end of study.
PROBLEM TO BE SOLVED: To provide methods for treating gastrointestinal inflammatory disorders such as inflammatory bowel disease including ulcerative colitis and Crohn's disease.SOLUTION: The invention provides a method for administering an integrin beta7 antagonist to a patient, where the integrin beta7 antagonist is subcutaneously administered. The integrin beta7 antagonist may be a monoclonal anti-beta7 antibody. The anti-beta7 antibody may be administered at a dose of 0.5 mg/kg, 1.5 mg/kg, 3.0 mg/kg or 4.0 mg/kg. The anti-beta7 antibody may be administered every four weeks. The anti-beta7 antibody may be administered for a period of 2, 3, 6, 12, 18, or 24 months, or for whole survival period of the patient. The anti-beta7 antibody may be selected from a chimeric antibody, a human antibody and a humanized antibody. The anti-beta7 antibody may be an antibody fragment.SELECTED DRAWING: None
The antibiotic BC 757, also known as pleuromutilin, is prepared by cultivating Clitopilus passeckerianus (Pil.) Sing. NRRL 3100, or a pleuromutilin-producing mutant or variant thereof, in an aqueous nutrient medium containing assimilable sources of carbon and nitrogen.  The antibiotic may be isolated by conventional methods for the isolation of pleuromutilin from a fermentation broth. Pleuromutilin is a growth stimulant and may be added to animal feeds to form a feed supplement or a ready-mixed feed.  For this purpose, the dried fermentation broth may be used. Conventional feed supplements containing penicillium mycelia may be used.
A composition suitable for activating cyclic adenosine monophosphate (cAMP) response component in vivo and an herbal plant composition utilized for preventing and improving osteopenia and osteoporosis are disclosed, and more particularly an effective part and a preparation method in the Chinese herbal composition and a preparation method thereof are disclosed. An active ingredient of the composition includes I) Epimedium grandiflorum Morr. genus, II) Drynaria fortune genus, and III) at least one of Chinese angelica genus, sage genus or lyceum genus. In some specific embodiments, the composition consists of active ingredients. In other words, the composition consists of Epimedium grandiflorum Morr. genus, Drynaria fortune genus, and at least one of Chinese angelica genus, sage genus or lyceum genus. In a specific first embodiment, the active ingredients of the composition consist of Epimedium grandiflorum Morr. genus, Drynaria fortune genus, and Chinese angelica genus. In a specific second embodiment, the active ingredients of the composition consist of Epimedium grandiflorum Morr. genus, Drynaria fortune genus, and sage genus. In a third specific embodiment, the active ingredients of the composition consist of Epimedium grandiflorum Morr. genus, Drynaria fortune genus, and lyceum genus. In various specific embodiments, the composition further comprises an inactive substance, in addition to the active ingredients. A method for preparing the composition is further disclosed.
ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE Inhibitors.  
Aspirin: As with other NSAIDs, concomitant administration of tolmetin sodium and aspirin is not generally recommended because of the potential of increased adverse effects.

Diuretics: Clinical studies, as well as post-marketing observations have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.

Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.

Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.

Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.

The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. However, increased prothrombin time and bleeding have been reported in patients on concomitant tolmetin and warfarin therapy. Therefore, caution should be exercised when administering tolmetin to patients on anticoagulants.

Hypoglycemic Agents: In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolmetin or the hypoglycemic agents.
Background: This study aimed to develop a combined ultrasound (US)-pathology model to predict the axillary status more accurately after NST in breast cancer. Methods: This retrospective study included breast cancer patients who received NST at the First Affiliated Hospital of Nanjing Medical University from 2015 to 2022. Clinical, US, and pathological data were collected. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of axillary pathological complete response (pCR). The model was developed using the predictors and validated. Results: A total of 657 patients were enrolled in this study. Two multivariate logistic analyses were performed before and after the operation. The results showed that the clinical lymph nodes, ER status, HER2 status, chemotherapy response of primary tumor, hilum structure of axillary lymph nodes (ALNs) after NST, blood flow of ALNs after NST, vascular invasion, pathological size, and Miller-Payne grade (all p < 0.05) were independent predictors of axillary pCR. The US-based and combined US-pathology models were developed based on preoperative and postoperative information. The two models had an area under the receiver operating characteristic curve (AUC) of 0.821 and 0.883, respectively, which was significantly higher than that of the fine-needle aspiration model (AUC: 0.735). Conclusion: In this study, based on the US-based model, a combined model incorporating the characteristics of ALNs under US and breast pathology was developed and validated to predict axillary pCR.
This is a non-profit study of a cohort of patients with Creatine Deficiency Syndromes genetically determined as CTD, GAMT-D and age-matched healthy controls. The design of the study is observational, case-control. An imaging session using fNIRS (NIRSport2, NIRx Technologies) will be conducted during the visits scheduled for the individual participants. Participants will be assessed for optimal placement of the fNIRS probe on the head through measurement of the fiducial points on the scalp. With the NIRx NIRSPort2 system, the near-infrared sources and detectors are situated in a fabric cap resembling a swim cap that is applied like a hat and secured in place by a velcro chin strap. Once the probe is placed, fNIRS will be measured during a passive viewing/listening task administered on a computer. The montage consists of 8 red light-sources operating at 760 nm and 850 nm, and 7 detectors which can be easily placed into a textile EEG cap (EASYCAP, Herrsching, Germany, size according to head circumference). The systems that are utilized have been selected to be very child-friendly systems, involving no cleaning or abrasion of the scalp preparation and rapid application. Application procedures have been designed to minimize any discomfort to the participant. In parallel, ECG will be collected using the polygraphic input box that integrates the ECG with the fNIRS. ECG records the electrical activity generated by the heart and can be used to derive both the heart rate and the pattern of electrical activity as it moves through the heart. To measure ECG, two electrodes will be applied to the skin over the lower left ribcage and the upper right collar bone after the skin has been cleansed and prepared with either abrasive paper or preparation gel. In total, these measurements should take 30-40 minutes to complete (including application of the NIRS cap). Alongside fNIRS, neuropsychological assessments of affected individuals patients will be conducted. The following outcome measures will be collected assessing: i) cognitive performance (Leiter International Performance Scale, 3rd edition, PPVT-5, simple reasoning tasks on tablets and Vineland Adaptive Behaviour Scale); ii) behavioural disorder (BASC-3 and ABC-2 scales); iii) autistic-like features (SRS-2 and PPD-MRS). The cognitive tasks were chosen to be adapted to the cognitive deficit of affected individuals. A task on tablets with minimal verbal instruction will allow to assess reasoning abilities in severe to moderate ID patients that could not perform classical Wechsler scale (IQ test). Healthy controls will be asked to return 8-12 weeks post their initial visit to undergo repeat fNIRS testing for the purposes of examining test-retest reliability of the fNIRS measurement. If their schedule allows, affected individuals will also undergo repeat fNIRS testing. fNIRS is safe, non-invasive and generally well tolerated. The information obtained from this study will help identify outcome measures for drug testing in future therapeutic trials.